医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit

2017年03月30日 PM06:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Takeda Pharmaceuticals Company Limited (“Takeda”), announced today that Ricardo Marek has been appointed as the President of the Emerging Markets Business Unit (EM BU), based in Singapore, effective April 1, 2017. In his new role he will lead all business operations across five geographic Areas that comprise EM BU – Asia Pacific (excluding Japan), China, Latin America, Middle East & Africa and Russia-CIS. Marek will also serve as a Corporate Officer and member of Takeda’s Executive Team, and report to Christophe Weber, President and Chief Executive Officer of Takeda.

After joining Takeda in 2011, Ricardo became President of Takeda Brazil in 2013. He then took-on additional, concurrent responsibilities, as Area Head of Latin America (LatAm) in 2014. Ricardo will be relocating from his home in São Paulo, Brazil, to Singapore and succeeds Giles Platford who has moved to Zurich as President of Europe and Canada, also effective April 1, 2017.

“The Emerging Markets is one of Takeda’s core growth drivers. Ricardo’s success in delivering solid growth in Latin America over the last six years, coupled with his strong leadership skills and commercial acumen makes him well placed to lead this business unit,” commented Christophe Weber, President & CEO of Takeda. “Ricardo has an impressive track-record spanning over 15 years in leadership positions. I am confident he will continue to lead our teams to great success in their work to deliver better health and a brighter future to patients.”

Marek’s experience also includes completing strategic acquisitions for Takeda across LatAm as well as launching the Oncology business in that part of the world for some of Takeda’s potentially life-saving and life-transforming medicines. His commitment to his employees and the development of talent has resulted in the countries under his remit being recognized with external awards from both the Great Place to Work ® and Top Employer ® Institutes. He holds an MBA from the University of São Paulo, Brazil.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005433/en/

CONTACT

Takeda Pharmaceuticals Company Limited
Emerging Markets
Headquarters (Singapore) and interview request with new EM President
Rebecca
Northridge
Rebecca.northridge@takeda.com
Asia
Pacific:
South Korea, Thailand, Australia, Indonesia and Taiwan
Gayatri
Narayanan
Gayatri.narayanan@takeda.com
China:
Hong
Kong, China
Chris Wu
Chris.wu@takeda.com
Near
East, Middle East, Africa:
Saudi Arabia, Turkey and Ukraine
Lamia
Hotait
Lamia.hotait@takeda.com
Russia
CIS:
Georgy Soustin
Russia and Kazakhstan
Georgy.soustin@takeda.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表